Navigation Links
Tomophase and MOSS, S.p.A. Expand OCTIS Technology Throughout Italy with New Distribution Agreement
Date:3/26/2013

BURLINGTON, Mass., March 26, 2013 /PRNewswire/ -- Tomophase Corporation, a leading developer of minimally invasive optical coherence tomography (OCT) tissue imaging devices, announced today that it has signed a distribution agreement with MOSS S.p.A. of Italy.

The distribution agreement with MOSS covers the Tomophase product line including the OCT Imaging System, OCTIS™ and the OCTIS Probes in the territory Italy and San Marino. Upon signing, MOSS also purchased two systems for waiting Italian clinicians who are experts in pulmonary imaging. Delivery and installation of OCTIS is scheduled for June. These new systems for Italian medical centers follow the deployment and installation of OCTIS in Germany at the Thoraxklinik, University of Heidelberg.  Both MOSS and Tomophase will work together to expand the availability of this innovative and much anticipated technology to the Italian medical community. 

"We are delighted to have MOSS as our distributor in Italy. President Franco Papa and his team have been very active with innovative imaging technologies and have been following our progress at Tomophase. We look forward to close cooperation with MOSS as they extend our OCTIS technology for interventional pulmonology throughout Italy," said Ralph Johnston , President and CEO. 

Dr. Peter Norris , Tomophase Executive Chairman commented, "The partnership of Tomophase with Franco Papa and MOSS is another example of the high level of international interest in the OCTIS platform. With their experience in Interventional Pulmonology, MOSS is an excellent fit for OCTIS and our goal of introducing physicians to the greatly expanded pulmonary imaging capabilities it affords. The placement of OCTIS units in two major pulmonary centers in Italy is a major step forward in meeting this goal."

Mr. Franco Papa , MOSS President and CEO, personally expressed, "MOSS has specialized through the years in identifying high-tech, innovative solutions which may provide concrete answers to our end users' most specific therapeutic demands. Therefore we welcome the opportunity to partner with an outstanding company like Tomophase for the purpose of developing the national market by means of such a strategic collaboration and, thus, achieve a successful introduction of the Tomophase OCT Imaging System in the field."

About MOSS
MOSS was founded to further the idea of creating an active platform for young and dynamic companies in order to offer foreign-based advanced medical device manufacturers a local, operating interface to support their needs and requirements throughout Italy. 

About Tomophase
Tomophase is a leader in developing bronchoscopic-based systems for interventional pulmonology. Offering significantly higher resolution than either CT scan or ultrasound, OCTIS provides real-time, high resolution, sub-surface tissue imaging of airways and lungs, to be followed by diagnostic and therapeutic applications. Our goal is to provide physicians with heretofore unobtainable airway microstructural images to improve the management and clinical outcome of pulmonary disease. The company has 28 patent and applications issued and pending. FDA 510(k) clearance for OCTIS was received and the CE Mark is expected in June. The U.S. commercial launch is underway and the EU rollout is proceeding. The company is currently raising investment capital to meet the increasing international demand for the OCT Imaging System.  Examples of our tissue imaging results are available at www.tomophase.com. For further information:In USA:Dr. Peter Norris, Executive Chairman 

Ralph Johnston, President, CEOTomophase CorporationTomophase CorporationP: (781) 229-57P: (781) 229-5700, ext 123 EmailEmailIn Italy: MOSS S.p.A.Via all'Erno, 528040 Lesa (NO) – ItalyTel. No.: +39 0322 772032Fax No.: +39 0322 292733EmailThis press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Tomophase Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
2. Alliqua Initiates Life-Cycle Management Plan to Expand Wound Care Portfolio for Use in Broader Wound Indications
3. Galderma, One of the Leading Pharmaceutical Companies, Relies on Verizon Enterprise Solutions to Provide Expanded, Secure Global Communications Platform
4. Torrance Memorial Medical Center Boosts Patient Safety With Expanded Use Of Capnography Technology
5. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
6. Cellular Dynamics Announces Presentations at the Society of Toxicologys 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
7. PET/MR Scanner Holds Promise For Expanded Diagnostics
8. BioElectronics Expands European Distribution to Malta
9. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
10. SAFC Expands PharmaGrade Raw Materials Portfolio to Meet Growing Demand; Expects to Double PharmaGrade Portfolio in 2013
11. Hyland Software and Merge Healthcare Expand Partnership to Provide Best of Breed ECM and VNA Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
(Date:7/31/2017)... Pharmacy, Inc. (NYSE: DPLO), has been named one of the ... Crain,s Detroit Business . The annual Crain,s Fast ... growth. This year,s edition measures growth from 2013 to 2016. ... list, visit crainsdetroit.com/awards/fast_50/2017 .  "Being named ... Phil Hagerman , CEO and chairman of Diplomat. "We,ve made ...
(Date:7/27/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... 30, 2017.  The Company reported second quarter net sales ... prior year period, and an increase of 2.1% on ... of contribution from the LDR Holding Corporation acquisition, second ... of 2016, or 0.3% on a constant currency basis. ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... ... past six years, Lightning Labels has sent out a call for users of its custom ... creativity of their designs. Submissions this year were open from May 18 to July 1 ... winners of the sixth annual Photo Contest, along with the prizes they've received:, ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Wilderness Voices”: a collection ... travel. “Wilderness Voices” is the creation of published author, Martha McKown, an ordained ... was inspired as a very young child when her older sisters studied High School ...
(Date:8/22/2017)... ... , ... TopConsumerReviews.com recently gave a best-in-class 5-star rating to Energy NADH, a ... of modern life continually makes more demands on time and energy, people are finding ... people in vicious high/low cycles and can also cause long term health issues. More ...
(Date:8/21/2017)... ... August 22, 2017 , ... ... I. Stevens as a 2017-2018 inductee into its VIP Woman of the ... NAPW is the nation’s leading networking organization exclusively for professional women, boasting more ...
(Date:8/21/2017)... ... 2017 , ... Marathon running has surged in popularity in ... running increases exposure to ultraviolet radiation, a carcinogen that promotes skin cancer. Studies ... half may be adequately protecting themselves with proper clothing and sunscreen. , ...
Breaking Medicine News(10 mins):